SHetA2 exhibits cytotoxicity against cancer cells (IC50: 0.37–4.6 μM); induces apoptosis via the mitochondrial intrinsic pathway; regulates cancer cell differentiation; arrests the cell cycle at the G2 phase; demonstrates in vivo antitumor activity in mice; possesses favorable pharmacokinetic properties; and is orally active.